Silexion Therapeutics Corp SLXN

Healthcare Biotechnology

Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

NDAQ:SLXN - Post by User

Silexion Therapeutics Corp

<< Previous

Bullboard Posts

Post by ProfitLens2001on Nov 20, 2024 12:48pm

17 Views

Post# 36322046

SLXN Soars on Major Stake News; Biotech Breakouts Heat Up

A sharp premarket rally in SLXN followed the revelation that a China-Israel biotech investment fund had acquired a 13.8% stake in Silexion.
The stock broke through its descending trendline with a surge in volume, as 35 million shares traded hands compared to the average daily volume of just 2.7M.
MYNZ, another biotech on my radar, has also crossed its descending trendline.

<< Previous

Bullboard Posts

Two micro-cap stocks with strong fundamentals